Speakers - CARWC2025

Abstract

Premature ageing of the skin is increasingly recognised not simply as a cosmetic concern, but as a systemic issue - one linked to long-term physiological stress and imbalance. Ageing leads to the thinning of both the dermis and epidermis, loss of volume in the hypodermis, and the breakdown of collagen and elastin. This results in decreased elasticity, dryness, impaired barrier function, and visible signs of degeneration. Studies have shown a decrease in both collagen I and III in ageing and sun-exposed skin, with collagen III declining more rapidly. AEQUILScience has developed a novel biophysical method to counteract these processes. Using a double patent-pending technology, we created Liquid Intelligence™ (LQTM) - electrovibrated water by low-frequency low energy electromagnetic fields (10–30,000 Hz, in the microTesla range, with 207 harmonics). In an exploratory study, we evaluated the tolerance and potential regenerative effect of LQTM using Reconstructed Human Epidermis (RHE) models. To simulate compromised skin, cytokines (IL-4, IL-13, IL-17E, IL-31, and TNF-α) were introduced from day 6 to 10 to induce barrier dysfunction. RHEs treated with LQTM showed normal epidermal morphology and intact stratification. Increased basal layer density and keratohyalin granules were observed, suggesting enhanced differentiation. Impermeability at the stratum corneum level remained intact, and a Lucifer Yellow diffusion test indicated improved intercellular exchange. Cell viability increased to over 100%, suggesting boosted proliferation. LQTM also demonstrated the potential to counteract cytokine-induced spongiosis, possibly via anti-inflammatory or mechanical effects. In a second study using immunohistochemistry, collagen I expression increased significantly in treated samples (n=240) versus controls (n=240), with a 64% increase (p<0.01). These findings suggest that electrovibrated water could play a therapeutic role in addressing premature ageing, restoring cellular coherence, and promoting dynamic tissue balance. Larger clinical trials are now being planned.